Articles Resources
    00Articles · Article

    Can AI Be Trusted With Sensitive Drug-Development Information?

    Trust should be an evidence decision. Eight questions help pharma and biotech buyers test how an AI provider uses, retains, accesses, routes, governs, and protects sensitive information.

    · 10 min read

    Published

    Yes, but only when trust is earned through evidence and matched to the intended use. Before sensitive drug-development information is uploaded, a buyer should be able to verify how the provider uses, retains, accesses, routes, monitors, and contractually protects that information, and how the AI system is governed over time.

    Consider an illustrative biotech company evaluating an AI platform for an IND-readiness pilot. The proposed upload includes an unpublished toxicology report, Investigator's Brochure, clinical protocol, CMC development summary, and regulatory correspondence. The demonstration is impressive. Procurement asks a more important question: what evidence should we see before any of those files leave our controlled environment?

    What information and use are being approved?

    Vendor review should start with context of use and information classification. A demonstration using public literature does not create the same exposure as a pilot using confidential CMC records. Personal data adds privacy obligations. Records or outputs used in a regulated workflow may add quality, validation, documentation, and change-control expectations. The decision should identify both the information entering the system and the decision or record the output may influence.

    The FDA and EMA's 2026 principles for good AI practice in drug development emphasize a risk-based approach, a clear context of use, multidisciplinary expertise, data governance and documentation, performance assessment, and lifecycle management. They are guiding principles, not a vendor certification or a substitute for requirements that apply to a sponsor's particular activity.

    Which eight questions should an AI vendor answer?

    • 1. Permitted data use and model training. What may the provider do with uploaded files, prompts, outputs, metadata, and feedback? Does any customer information improve models or services, and can that use be disabled contractually?
    • 2. Retention, backups, deletion, and verification. How long are source files, derived data, logs, and backups retained? What happens at pilot end or contract termination, and how can deletion be requested and verified?
    • 3. Identity, roles, privileged access, and tenant separation. Who can access customer information, under which roles and circumstances, how is privileged access approved and reviewed, and how are customers and projects separated?
    • 4. Subprocessors, data flow, and residency. Which hosting, model, storage, analytics, and support providers receive information? Where is it processed or stored, and how is a material subprocessor change communicated?
    • 5. Logging, monitoring, incident response, and notification. Which user and administrative events are recorded? How is suspicious activity detected, investigated, contained, and reported to the customer?
    • 6. Contracts, assurance reports, and evidence currency. Which commitments are contractual, which are policy statements, and which have independent assurance? Are reports current and relevant to the service and controls being purchased?
    • 7. Model and output governance. Who reviews outputs, how are limitations communicated, what traceability is retained, and how are model, prompt, retrieval, or configuration changes assessed before they affect the approved use?
    • 8. Business continuity, exit, export, and replacement. How does the service recover from disruption? Can the sponsor export its information in a usable form, preserve required records, and replace the vendor without losing traceability?

    NIST's AI Risk Management Framework is a voluntary, cross-sector framework organized around governing, mapping, measuring, and managing AI risk. Its Generative AI Profile adds considerations specific to generative systems. These resources can structure diligence, but they do not determine whether a particular pharma use is compliant or validated.

    What evidence should a buyer request?

    AI vendor due diligence evidence checklist
    Question to askEvidence to requestWarning sign
    How may our data be used?Contract terms, privacy terms, product settings, and a written explanation of training and secondary useBroad rights to reuse customer content or answers limited to marketing language
    How is information deleted?Retention schedule, backup lifecycle, deletion process, and available confirmationNo defined schedule or deletion that excludes derived data without explanation
    Who can access it?Role matrix, privileged-access process, access-review evidence, and tenant-separation descriptionShared credentials, standing privileged access, or unclear customer separation
    Where does it travel?Current subprocessor list, data-flow diagram, processing locations, and change-notice termsAn incomplete list or no account of model-provider data handling
    How are incidents handled?Incident-response plan, monitoring scope, notification terms, and relevant exercise evidenceNo notification commitment or no owner for investigating suspicious access
    What has been independently assessed?Current assurance report, scope, exceptions, remediation status, and contract mappingA certification logo without scope, date, or applicable service details
    How are outputs governed?Human-review controls, validation or evaluation records, version history, limitations, and change processOutputs treated as authoritative or material changes made without notice or assessment
    How do we exit or recover?Continuity and recovery plan, tested export, termination assistance, and record-preservation termsProprietary lock-in with no usable export or continuity evidence

    How should the evidence change the procurement decision?

    Suppose the provider documents acceptable data-use terms and access controls but cannot provide a defined retention schedule or enough detail about a model subprocessor. The sponsor does not need to reduce the decision to approve or reject. It can approve a public-information demonstration, approve a pilot with redacted or lower-sensitivity documents, require missing controls before confidential upload, or defer the use entirely.

    The right outcome depends on the sponsor's information classification, intended use, applicable obligations, risk tolerance, and ability to add compensating controls. What matters is that the decision is based on documented facts, unresolved questions, and explicit restrictions rather than assumptions created by the word secure.

    What does security evidence not establish?

    Information security, privacy and data protection, and fitness for a regulated or GxP use are related but separate determinations. A security report may support confidence that specified controls were assessed during a defined period. It does not, by itself, establish lawful processing, validate an intended use, demonstrate that an output is scientifically reliable, or make the sponsor's workflow compliant.

    The reverse is also true. A technically strong model is not automatically appropriate for confidential information. A contract does not prove that controls operate effectively. Encryption does not answer whether the provider is permitted to retain or reuse content. Each form of evidence answers a different question, so procurement, security, privacy, quality, regulatory, scientific, and business owners may all need to participate according to the use case.

    The decision in eight lines

    • Know what the provider may do with the data.
    • Know how long every relevant copy remains and how deletion is verified.
    • Know who can gain access and how customers are separated.
    • Know every material destination in the data flow.
    • Know what is logged and what happens after an incident.
    • Know which commitments are contractual and which evidence is current.
    • Know how outputs and system changes are reviewed and traced.
    • Know how to recover, export, preserve records, and leave.

    Trust is not a product feature that a buyer accepts on assertion. It is a scoped decision supported by evidence, documented limits, and ongoing review. That same discipline underlies regulatory readiness as a decision and the move from evidence to action.

    Sources

    This article is general information on public regulatory requirements. It is not regulatory or legal advice, and Alenvo is not affiliated with FDA. Read our editorial standards.

    Put this into practice.

    See how Alenvo helps teams connect evidence, gaps, and decisions across an IND program.

    Related articles

    Alenvo, Inc.

    Regulatory intelligence built for the highest-stakes moments in drug development.

    From first-in-human to first approval. Two products covering IND readiness and NDA filing-gate intelligence across 505(b)(1), 505(b)(2), and biosimilar pathways.

    © 2026 Alenvo, Inc. All rights reserved.

    Built for biotech and pharmaceutical regulatory affairs teams.